July 29, 2024 01:40 PM EDT
Pharma
FDA+

As­traZeneca and Dai­ichi Sankyo fail to win NICE rec­om­men­da­tion for En­her­tu, call for change to re­view process

Nicole DeFeudis

Editor

The Unit­ed King­dom’s drug pric­ing watch­dog has of­fi­cial­ly de­clined to rec­om­mend As­traZeneca and Dai­ichi Sankyo’s En­her­tu for HER2-low breast can­cer in the UK, not­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times